Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice

被引：16

作者：

Schackman, Bruce R. ^{[1
]}

Haas, David W. ^{[2
]}

Park, Sanghee S. ^{[3
]}

Li, X. Cynthia ^{[3
]}

Freedberg, Kenneth A. ^{[3
,4
,5
]}

机构：

[1] Weill Cornell Med Coll, Dept Healthcare Policy & Res, New York, NY 10065 USA

[2] Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA

[3] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Div Gen Internal Med, Boston, MA 02114 USA

[4] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA

[5] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 18期

关键词：

antiretroviral therapy; cost-effectiveness; dose optimization; genotyping; HIV; INITIAL ANTIRETROVIRAL THERAPY; PLASMA-CONCENTRATIONS; DOSE REDUCTION; DOUBLE-BLIND; REGIMENS; PHARMACOKINETICS; POLYMORPHISMS; COMBINATION; METABOLISM; INFECTION;

D O I：

10.2217/pgs.15.142

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To assess the cost-effectiveness of CYP2B6 genotyping to guide efavirenz dosing for initial HIV therapy in the USA. Methods: We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) microsimulation model to project quality-adjusted life expectancy and lifetime costs (2014 US dollars) for efavirenz-based HIV therapy with or without CYP2B6 genotyping. We assumed that with genotyping 60% of patients would be eligible to receive lower doses. Results: Current care without CYP2B6 genotyping has an incremental cost-effectiveness ratio >$100,000/QALY compared with genotype-guided dosing, even if lower dosing reduces efficacy. When we assumed generic efavirenz availability, conclusions were similar unless lower dosing reduces efficacy by 6% or more. Conclusion: CYP2B6 genotyping can inform efavirenz dosing and decrease HIV therapy cost.

引用

页码：2007 / 2018

页数：12

共 51 条

[41] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks [J].

Sax, Paul E. ;

DeJesus, Edwin ;

Mills, Anthony ;

Zolopa, Andrew ;

Cohen, Calvin ;

Wohl, David ;

Gallant, Joel E. ;

Liu, Hui C. ;

Zhong, Lijie ;

Yale, Kitty ;

White, Kirsten ;

Kearney, Brian P. ;

Szwarcberg, Javier ;

Quirk, Erin ;

Cheng, Andrew K. .

LANCET, 2012, 379 (9835) :2439-2448

[42] Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States [J].

Sax, Paul E. ;

Meyers, Juliana L. ;

Mugavero, Michael ;

Davis, Keith L. .

PLOS ONE, 2012, 7 (02)

[43] The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV [J].

Schackman, Bruce R. ;

Scott, Callie A. ;

Walensky, Rochelle P. ;

Losina, Elena ;

Freedberg, Kenneth A. ;

Sax, Paul E. .

AIDS, 2008, 22 (15) :2025-2033

[44]

Schackman BR, 2015, MED CARE, V53, P293, DOI 10.1097/MLR.0000000000000308

[45] Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease [J].

Schackman, Bruce R. ;

Haas, David W. ;

Becker, Jessica E. ;

Berkowitz, Bethany K. ;

Sax, Paul E. ;

Daar, Eric S. ;

Ribaudo, Heather J. ;

Freedberg, Kenneth A. .

ANTIVIRAL THERAPY, 2013, 18 (03) :399-408

[46] Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals [J].

Scourfield, Andrew ;

Zheng, Jiexin ;

Chinthapalli, Suchitra ;

Waters, Laura ;

Martin, Thomas ;

Mandalia, Sundhiya ;

Nelson, Mark .

AIDS, 2012, 26 (11) :1399-1401

[47] No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART [J].

Takahashi, Masaaki ;

Ibe, Shiro ;

Kudaka, Yuichi ;

Okumura, Naoya ;

Hirano, Atsushi ;

Suzuki, Tatsuo ;

Mamiya, Naoto ;

Hamaguchi, Motohiro ;

Kaneda, Tsuguhiro .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (08) :983-987

[48]

Thomson Corporation, 2014, RED BOOK PHARM FUND

[49] Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study [J].

van Leth, F ;

Phanuphak, P ;

Ruxrungtham, K ;

Baraldi, E ;

Miller, S ;

Gazzard, B ;

Cahn, P ;

Lalloo, UG ;

van der Westhuizen, IP ;

Malan, DR ;

Johnson, MA ;

Santos, BR ;

Mulcahy, F ;

Wood, R ;

Levi, GC ;

Reboredo, G ;

Squires, K ;

Cassetti, I ;

Petit, D ;

Raffi, F ;

Katlama, C ;

Murphy, RL ;

Horban, A ;

Dam, JP ;

Hassink, E ;

van Leeuwen, R ;

Robinson, P ;

Wit, FW ;

Lange, JMA .

LANCET, 2004, 363 (9417) :1253-1263

[50] Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States [J].

Walensky, Rochelle P. ;

Sax, Paul E. ;

Nakamura, Yoriko M. ;

Weinstein, Milton C. ;

Pei, Pamela P. ;

Freedberg, Kenneth A. ;

Paltiel, A. David ;

Schackman, Bruce R. .

ANNALS OF INTERNAL MEDICINE, 2013, 158 (02) :84-+

← 1 2 3 4 5 6 →